Dual-Targeting of AR and Akt Pathways by Berberine in Castration-Resistant Prostate Cancer
Abstract
In this grant period, we tested the efficacy of berberine against castration-resistance prostate cancer driven by a constitutively active AR splice variant. While berberine treatment significantly inhibited the growth of tumor xenografts harboring ARv567es, the FDA approved potent antiandrogen enzalutamide treatment failed to exert inhibitory effects in this model of prostate cancer. More importantly, BBR treatment sensitized the AR-V-expressing tumors to enzalutamide, providing proof-of-principle for developing combination strategies using berberine and enzalutamide in prostate cancer expression AR splice variants
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2015
- Accession Number
- AD1001314
Entities
People
- Haitao Zhang
Organizations
- Tulane University of Louisiana